Glyoxalase I Antibody (6F10): sc-101537
- Glyoxalase I Antibody (6F10) is a rat monoclonal IgG2b, cited in 5 publications, provided at 200 µg/ml
- raised against full-length Glyoxalase I of mouse origin
- recommended for detection of Glyoxalase I of mouse, rat, human and monkey origin by WB, IP, IF and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Glyoxalase I Antibody (6F10). This work is in progress.
QUICK LINKS
Glyoxalase I Antibody (6F10) is a rat monoclonal IgG2b antibody that detects Glyoxalase I in mouse, rat, human, and monkey samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Glyoxalase I (GLO1) plays a crucial role in the detoxification of glucose degradation products, which is vital for cellular health and metabolic balance. GLO1 antibody (6F10) targets a protein primarily located in the cytoplasm, where GLO1 catalyzes the conversion of methylglyoxal to D-lactate, thereby preventing the accumulation of toxic byproducts that can lead to cellular stress and damage. Glyoxalase I′s cellular location enables rapid response to fluctuations in metabolic byproducts, making GLO1 essential for maintaining cellular homeostasis. GLO1 has been implicated in various physiological processes, including the modulation of anxiety-related behaviors, as evidenced by studies showing that GLO1 expression levels can influence anxiety responses in animal models. The presence of specific regulatory elements in the GLO1 gene promoter, such as the insulin response element and zinc metal response element, further highlights GLO1′s significance in metabolic regulation and potential role in cancer biology, particularly in colon carcinoma, where GLO1 expression is notably induced. Anti-Glyoxalase I antibody (6F10) serves as an invaluable tool for researchers investigating the multifaceted roles of GLO1 in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Glyoxalase I Antibody (6F10) References:
- Glyoxalase I inhibitors in cancer chemotherapy. | Creighton, DJ., et al. 2003. Biochem Soc Trans. 31: 1378-82. PMID: 14641067
- Methylglyoxal and glyoxalase I in atherosclerosis. | Hanssen, NM., et al. 2014. Biochem Soc Trans. 42: 443-9. PMID: 24646258
- Glyoxalase I (Glo1) and its metabolites in vascular disease. | Wortmann, M., et al. 2014. Biochem Soc Trans. 42: 528-33. PMID: 24646273
- Recent Advances in Glyoxalase-I Inhibition. | Al-Balas, QA., et al. 2019. Mini Rev Med Chem. 19: 281-291. PMID: 30306863
- Glyoxalase I-4 functions downstream of NAC72 to modulate downy mildew resistance in grapevine. | Li, T., et al. 2021. Plant J. 108: 394-410. PMID: 34318550
- Design, Synthesis and Biological Evaluation of 1,4-Benzenesulfonamide Derivatives as Glyoxalase I Inhibitors. | Audat, SA., et al. 2022. Drug Des Devel Ther. 16: 873-885. PMID: 35378924
- Glyoxalase I activity affects Arabidopsis sensitivity to ammonium nutrition. | Borysiuk, K., et al. 2022. Plant Cell Rep. 41: 2393-2413. PMID: 36242617
- Triphenylbismuth dichloride inhibits human glyoxalase I and induces cytotoxicity in cultured cancer cell lines. | Takasawa, R., et al. 2022. J Toxicol Sci. 47: 539-546. PMID: 36450498
- Role of glyoxalase I and II in somatic and spermatogenic testicular cells during the postnatal development of the domestic cat. | Braun, BC. and Müller, K. 2023. Theriogenology. 197: 10-15. PMID: 36462331
- Glyoxalase I is a novel target for the prevention of metabolic derangement. | Miranda, ER. and Haus, JM. 2023. Pharmacol Ther. 250: 108524. PMID: 37722607
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Glyoxalase I Antibody (6F10) | sc-101537 | 200 µg/ml | $322.00 |